Anatomy of risk evaluation and mitigation strategies (REMS)

Kari K. Loeser*, June M McKoy, Glen T. Schumock

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This Chapter provides an introduction and overview of the U.S. FDA REMS program and applicable regulatory aspects. Topics covered include the 2015 Draft Guidance, organization structure and functions, a discussion on pharmacovigilance and adverse event reports, and a discussion of the applicability of REMS in oncology.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Pages93-105
Number of pages13
DOIs
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
Volume171
ISSN (Print)0927-3042

Fingerprint

Anatomy
Pharmacovigilance

Keywords

  • CDER
  • Mitigation
  • OPDP
  • Oncology
  • Pharmaceuticals
  • Prescription drugs
  • REMS
  • Risk evaluation
  • U.S. food and drug administration (FDA)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Loeser, K. K., McKoy, J. M., & Schumock, G. T. (2019). Anatomy of risk evaluation and mitigation strategies (REMS). In Cancer Treatment and Research (pp. 93-105). (Cancer Treatment and Research; Vol. 171). Springer International Publishing. https://doi.org/10.1007/978-3-319-43896-2_7
Loeser, Kari K. ; McKoy, June M ; Schumock, Glen T. / Anatomy of risk evaluation and mitigation strategies (REMS). Cancer Treatment and Research. Springer International Publishing, 2019. pp. 93-105 (Cancer Treatment and Research).
@inbook{19f33beda31148fea8ace9cc409e08df,
title = "Anatomy of risk evaluation and mitigation strategies (REMS)",
abstract = "This Chapter provides an introduction and overview of the U.S. FDA REMS program and applicable regulatory aspects. Topics covered include the 2015 Draft Guidance, organization structure and functions, a discussion on pharmacovigilance and adverse event reports, and a discussion of the applicability of REMS in oncology.",
keywords = "CDER, Mitigation, OPDP, Oncology, Pharmaceuticals, Prescription drugs, REMS, Risk evaluation, U.S. food and drug administration (FDA)",
author = "Loeser, {Kari K.} and McKoy, {June M} and Schumock, {Glen T.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-3-319-43896-2_7",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Springer International Publishing",
pages = "93--105",
booktitle = "Cancer Treatment and Research",

}

Loeser, KK, McKoy, JM & Schumock, GT 2019, Anatomy of risk evaluation and mitigation strategies (REMS). in Cancer Treatment and Research. Cancer Treatment and Research, vol. 171, Springer International Publishing, pp. 93-105. https://doi.org/10.1007/978-3-319-43896-2_7

Anatomy of risk evaluation and mitigation strategies (REMS). / Loeser, Kari K.; McKoy, June M; Schumock, Glen T.

Cancer Treatment and Research. Springer International Publishing, 2019. p. 93-105 (Cancer Treatment and Research; Vol. 171).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Anatomy of risk evaluation and mitigation strategies (REMS)

AU - Loeser, Kari K.

AU - McKoy, June M

AU - Schumock, Glen T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - This Chapter provides an introduction and overview of the U.S. FDA REMS program and applicable regulatory aspects. Topics covered include the 2015 Draft Guidance, organization structure and functions, a discussion on pharmacovigilance and adverse event reports, and a discussion of the applicability of REMS in oncology.

AB - This Chapter provides an introduction and overview of the U.S. FDA REMS program and applicable regulatory aspects. Topics covered include the 2015 Draft Guidance, organization structure and functions, a discussion on pharmacovigilance and adverse event reports, and a discussion of the applicability of REMS in oncology.

KW - CDER

KW - Mitigation

KW - OPDP

KW - Oncology

KW - Pharmaceuticals

KW - Prescription drugs

KW - REMS

KW - Risk evaluation

KW - U.S. food and drug administration (FDA)

UR - http://www.scopus.com/inward/record.url?scp=85058945283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058945283&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-43896-2_7

DO - 10.1007/978-3-319-43896-2_7

M3 - Chapter

T3 - Cancer Treatment and Research

SP - 93

EP - 105

BT - Cancer Treatment and Research

PB - Springer International Publishing

ER -

Loeser KK, McKoy JM, Schumock GT. Anatomy of risk evaluation and mitigation strategies (REMS). In Cancer Treatment and Research. Springer International Publishing. 2019. p. 93-105. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-319-43896-2_7